LONDON – Agennix AG has reached the devastation point with the Phase III failure of its lead product talactoferrin in a 742-patient Phase III trial in lung cancer. Read More
DUBLIN, Ireland – The headline on a note from Jefferies & Co. research analyst Corey Davis said it all: "At least it's not ambiguous: Bapi's Dead." Read More
Myotonic dystrophy leads to muscle weakness – but also to cardiac arrhythmias, diabetes and cognitive disorders. In fact, Charles Thornton told BioWorld Today, "dystrophy is a bit of misnomer" for the disorder, which he considers closest to a neurodegenerative disease. Read More
With the prospect of using its vaccine technology to smite mosquito-borne dengue fever, Arbovax Inc. also hopes to become a giant-killer by besting big pharma attempts to prevent dengue and other insect-borne diseases. Read More
• Isis Pharmaceuticals Inc., of Carlsbad, Calif., said it plans to offer $175 million in aggregate principal of convertible senior notes due 2019 in a private placement. Read More
• ImaginAb Inc., of Los Angeles, signed a master service agreement with Singapore Radiopharmaceuticals Pte Ltd., a subsidiary of Fortis HealthCare, as part of its expansion program in Singapore. The agreement represents a formalization of a previous ad hoc collaboration. Read More
• Celsion Corp., of Lawrenceville, N.J., and Royal Philips Electronics, of Andover, Mass., said the FDA approved a Phase II study supporting a joint development program for ThermoDox, Celsion's heat-activated liposomal encapsulation of doxorubicin, in combination with Philips' Sonalleve MR-HIFU (MR-guided high intensity-focused ultrasound) technology for the palliation of painful bone metastases caused by lung, prostate or breast cancers. Read More
• Pfizer Inc., of New York, will pay more than $60 million to resolve Department of Justice (DOJ) and SEC investigations into improper payments made by two of its subsidiaries outside the U.S. Read More
